1015697-66-1

Basic information

• Product Name: 3-triphenylmethoxy-4-ethoxy benzaldehyde
• Synonyms: 3-triphenylmethoxy-4-ethoxy benzaldehyde
• CAS NO: 1015697-66-1
• Molecular Weight: 408.497
• Mol File: 1015697-66-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-triphenylmethoxy-4-ethoxy benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-triphenylmethoxy-4-ethoxy benzaldehyde(1015697-66-1)
• EPA Substance Registry System: 3-triphenylmethoxy-4-ethoxy benzaldehyde(1015697-66-1)

Safety Data

• Hazardous Substances Data: 1015697-66-1(Hazardous Substances Data)

Upstream product

• 2539-53-9 4-ethoxy-3-hydroxybenzaldehyde 
• 76-83-5 trityl chloride 

Downstream Products

• 1015697-67-2 C₃₈H₃₆O₅ 
• 1015697-59-2 (Z)-2-ethoxy-5-(3,4,5-trimethoxystyryl)phenol 

Relevant articles and documents

Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents

A series of combretastatin A-4 (CA-4) sulfamate derivatives were synthesized and their structure-activity relationship on tubulin, arylsulfatase and tumor cell antiproliferation inhibition was studied. Among them, compound 16a showed excellent potency as well as CA-4 under the same conditions against six tumor cells including HTC-116, HeLa, HepG2, MGC803, MKN45 and MCF-7 cells, respectively. Molecular docking revealed that several important hydrogen bond interactions were formed between the sulfamate group of 16a and the colchicine binding site of tubulin and steroid sulfatase respectively. Although compound 16a was less active than CA-4 in regard to its in vitro activity as an inhibitor of tubulin polymerization, it was effective as an inhibitor of arylsulfatase. This novel combretastatin A-4 sulfamate derivative has the potential to be developed as a dual inhibitor of tubulin polymerization and arylsulfatase for cancer therapy.

THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS

The invention disclosed a total synthesis process of novel ethoxy combretastatins and their prodrugs. Combretastatins are chemically modified by ethoxy substituted on the 4'-position of their B aryl ring and are converted to be their soluble prodrugs of phosphate or their inner salt of phosphorylcholine by modifying the hydroxyl on the 3'-position of their B aryl ring. Similarly, 3'-amino combretastatin is 4'-ethoxy chemically modified and further side chain of amino acid can be introduced to the amino to form soluble prodrug of amino acidamide. The structure of the said compound is showed as formula (I). Ethoxy combretastatins possess potent tubulin polymerization inhibitory activity and can be used for the treatment of inhibiting tumor or neovascular.